Hey workinman. My understanding is that the intended purpose of the phase I/II trial is to prove safety, but I also believe that management stated that they will report any positive side effects of the if/when they occur. They're able to do this as there's no control group receiving placebo in the trial, all of the applicant's will be receiving stem cell injections. So, basically if there's confirmed measurable vision improvement after the patients are injected during this phase I/II trial, the company will report it even though proving that there is vision improvement isn't the actual intended purpose of the trial. Rocky could probably verify this, but I'm quite certain I'm correct in what I'm stating.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.